Rezon Bio supports biologics programs across the full clinical and commercial supply continuum from a single partnership. The Gdansk site handles clinical-stage GMP manufacturing, while the Warsaw-Duchnice facility, FDA approved in February 2026 and equipped with up to 2x 2,000L single-use bioreactor capacity, supports late-phase clinical and commercial-scale production. Drug product development/formulation and manufacturing services are delivered through an integrated model with centralized program oversight and coordination. For programs moving from late-stage clinical into PPQ and commercial launch, continuity of partner, quality system, and technical team removes a significant source of risk.
Expert Insights
